Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy
- 28 January 2005
- journal article
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 139 (3) , 476-481
- https://doi.org/10.1016/j.ajo.2004.10.004
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathyAmerican Journal of Ophthalmology, 2002
- Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGFScience, 1999
- Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24American Journal of Ophthalmology, 1999
- Cell Type-Specific Expression of Angiopoietin-1 and Angiopoietin-2 Suggests a Role in Glioblastoma AngiogenesisThe American Journal of Pathology, 1998
- The 14-year incidence of visual loss in a diabetic population,Ophthalmology, 1998
- Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathyDiabetologia, 1997
- Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.Proceedings of the National Academy of Sciences, 1995
- Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.Proceedings of the National Academy of Sciences, 1995
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994
- Detection of Vascular Endothelial Growth Factor Messenger RNA and Vascular Endothelial Growth Factor-like Activity in Proliferative Diabetic RetinopathyArchives of Ophthalmology (1950), 1994